04:39 AM EDT, 09/16/2024 (MT Newswires) -- Replimune Group ( REPL ) said Sunday that an analysis of a trial of its drug RP1 combined with nivolumab showed "clinically meaningful and durable systemic anti-tumor activity" in patients with anti-PD1 failed melanoma.

The 140-patient study showed an overall response rate of 33.6%, meeting its primary endpoint, the company said.

Price: 11.22, Change: +0.09, Percent Change: +0.81